Phase 1 trial of a single dose of recombinant human interleukin-12 in human immunodeficiency virus-infected patients with 100-500 CD4 cells/μL

Mark A. Jacobson, David Hardy, Elizabeth Connick, Jessica Watson, Michael DeBruin

Research output: Contribution to journalArticlepeer-review

43 Scopus citations

Abstract

A phase 1 dose-escalation trial of a single subcutaneous dose of recombinant human (rh) interleukin (IL)-12 was conducted in medically stable human immunodeficiency virus (HIV)-infected patients with 100-500/μL absolute CD4+ T lymphocytes. Subjects at each dose level were randomly assigned (3:1) to receive rhIL-12 or placebo. Among the 47 subjects enrolled, rhIL-12 was well tolerated at doses of 3-300 ng/kg, but 4 of 5 subjects who received rhIL-12 at 1000 ng/kg had severe adverse events. Dose-related increases in serum interferon-γ occurred after rhIL-12 administration at doses ≥30 ng/kg. There was no effect of rhIL-12 on plasma HIV RNA or absolute CD4+ T cell counts. However, dose-related increases in absolute CD8+ T and NK cells were observed in subjects assigned to rhIL-12 doses of 30-300 ng/kg. Single rhIL-12 doses of 30-300 ng/kg were well tolerated and had biologic activity that could potentially be of benefit in the treatment of HIV disease or its complications.

Original languageEnglish (US)
Pages (from-to)1070-1076
Number of pages7
JournalJournal of Infectious Diseases
Volume182
Issue number4
DOIs
StatePublished - 2000
Externally publishedYes

ASJC Scopus subject areas

  • Immunology and Allergy
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Phase 1 trial of a single dose of recombinant human interleukin-12 in human immunodeficiency virus-infected patients with 100-500 CD4 cells/μL'. Together they form a unique fingerprint.

Cite this